Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

Authors: Solomon, Benjamin J, Bauer, Todd M, Mok, Tony S K, Liu, Geoffrey, Mazieres, Julien, de Marinis, Filippo, Goto, Yasushi, Kim, Dong-Wan, Wu, Yi-Long, Jassem, Jacek, López, Froylán López, Soo, Ross A, Shaw, Alice T, Polli, Anna, Messina, Rossella, Iadeluca, Laura, Toffalorio, Francesca, Felip, Enriqueta

Source: Lancet.Respiratory medicine. 11(4):354-366

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100186473790.0x000001&indx=1&recIds=ETOCvdc_100186473790.0x000001

Local ablative radiotherapy on oligo‐progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non–small cell lung cancer patients: A longer cohort

Authors: Mok, Florence Siu ting, Tong, Macy, Loong, Herbert H., Mok, Tony S. K.

Source: Asia-Pacific journal of clinical oncology. 18(6):614-624

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100164957754.0x000001&indx=1&recIds=ETOCvdc_100164957754.0x000001

Next-generation immunotherapy: igniting new hope for lung cancer.

Authors: Li, Molly S. C., Chan, Andrew L. S., Mok, Kevin K. S., Chan, Landon L., Mok, Tony S. K.

Source: Therapeutic Advances in Medical Oncology; 12/7/2024, p1-31, 31p

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Authors: Adamchuk, Grigory, Ahn, Myung-Ju, Alexandru, Aurelia, Altundag, Ozden, Alyasova, Anna, Andrusenko, Orest, Aoe, Keisuke, Araujo, Antonio, Aren, Osvaldo, Arrieta Rodriguez, Oscar, Ativitavas, Touch, Avendano, Oscar, Barata, Fernando, Barrios, Carlos Henrique, Beato, Carlos, Bergstrom, Per, Betticher, Daniel, Bolotina, Larisa, Bondarenko, Igor, Botha, Michiel, Buddu, Sayeuri, Caglevic, Christian, Cardona, Andres, Castro, Gilberto, Jr, Castro, Hugo, Cay Senler, Filiz, Cerny, Carlos Alexandre Sydow, Cesas, Alvydas, Chan, Gee-Chen, Chang, Jianhua, Chen, Gongyan, Chen, Xi, Cheng, Susanna, Cheng, Ying, Cherciu, Nelly, Chiu, Chao-Hua, Cho, Byoung Chul, Cicenas, Saulius, Ciurescu, Daniel, Cohen, Graham, Costa, Marcos Andre, Danchaivijitr, Pongwut, De Angelis, Flavia, de Azevedo, Sergio Jobim, Dediu, Mircea, Deliverski, Tsvetan, De Marchi, Pedro Rafael Martins, de The Bustamante Valles, Flor, Ding, Zhenyu, Doganov, Boyan, Dreosti, Lydia, Duarte, Ricardo, Edusma-Dy, Regina, Emelyanov, Sergey, Erman, Mustafa, Fan, Yun, Fein, Luis, Feng, Jifeng, Fenton, David, Fernandes, Gustavo, Ferreira, Carlos, Franke, Fabio Andre, Freitas, Helano, Fujisaka, Yasuhito, Galindo, Hector, Galvez, Christina, Ganea, Doina, Gil, Nuno, Girotto, Gustavo, Goker, Erdem, Goksel, Tuncay, Gomez Aubin, Gonzalo, Gomez Wolff, Luis, Griph, Hakan, Gumus, Mahmut, Hall, Jacqueline, Hart, Gregory, Havel, Libor, He, Jianxing, He, Yong, Hernandez Hernandez, Carlos, Hespanhol, Venceslau, Hirashima, Tomonori, Ho, Chung Man James, Horiike, Atsushi, Hosomi, Yukio, Hotta, Katsuyuki, Hou, Mei, How, Soon Hin, Hsia, Te-Chun, Hu, Yi, Ichiki, Masao, Imamura, Fumio, Ivashchuk, Oleksandr, Iwamoto, Yasuo, Jaal, Jana, Jassem, Jacek, Jordaan, Christa, Juergens, Rosalyn Anne, Kaen, Diego, Kalinka-Warzocha, Ewa, Karaseva, Nina, Karaszewska, Boguslawa, Kazarnowicz, Andrzej, Kasahara, Kazuo, Katakami, Nobuyuki, Kato, Terufumi, Kawaguchi, Tomoya, Kim, Joo Hang, Kishi, Kazuma, Kolek, Vitezslav, Koleva, Marchela, Kolman, Petr, Koubkova, Leona, Kowalyszyn, Ruben, Kowalski, Dariusz, Koynov, Krassimir, Ksienski, Doran, Kubota, Kaoru, Kudaba, Iveta, Kurata, Takayasu, Kuusk, Gerli, Kuzina, Lyudmila, Laczo, Ibolya, Ladrera, Guia Elena Imelda, Laktionov, Konstantin, Landers, Gregory, Lazarev, Sergey, Lerzo, Guillermo, Lesniewski Kmak, Krzysztof, Li, Wei, Liam, Chong Kin, Lifirenko, Igor, Lipatov, Oleg, Liu, Xiaoqing, Liu, Zhe, Lo, Sing Hung, Lopes, Valeria, Lopez, Karla, Lu, Shun, Martinengo, Gaston, Mas, Luis, Matrosova, Marina, Micheva, Rumyana, Milanova, Zhasmina, Miron, Lucian, Mok, Tony, Molina, Matias, Murakami, Shuji, Nakahara, Yasuharu, Nguyen, Tien Quang, Nishimura, Takashi, Ochsenbein, Adrian, Ohira, Tatsuo, Ohman, Ronny, Ong, Choo Khoon, Ostoros, Gyula, Ouyang, Xuenong, Ovchinnikova, Elena, Ozyilkan, Ozgur, Petruzelka, Lubos, Pham, Xuan Dung, Picon, Pablo, Piko, Bela, Poltoratsky, Artem, Ponomarova, Olga, Popelkova, Patrice, Purkalne, Gunta, Qin, Shukui, Ramlau, Rodryg, Rappaport, Bernardo, Rey, Felipe, Richardet, Eduardo, Roubec, Jaromir, Ruff, Paul, Rusyn, Andrii, Saka, Hideo, Salas, Jorge, Sandoval, Mario, Santos, Lucas, Sawa, Toshiyuki, Seetalarom, Kasan, Seker, Mesut, Seki, Nobuhiko, Seolwane, Freddy, Shepherd, Lucinda, Shevnya, Sergii, Shimada, Andrea Kazumi, Shparyk, Yaroslav, Sinielnikov, Ivan, Sirbu, Daniela, Smaletz, Oren, Soares, Joao Paulo Holanda, Sookprasert, Aumkhae, Speranza, Giovanna, Srimuninnimit, Vichien, Sriuranpong, Virote, Stara, Zinaida, Su, Wu-Chou, Sugawara, Shunichi, Szpak, Waldemar, Takahashi, Kazuhisa, Takigawa, Nagio, Tanaka, Hiroshi, Tan Chun Bing, Jerry, Tang, Qiyou, Taranov, Pavel, Tejada, Hermes, Tho, Lye Mun, Torii, Yoshitaro, Trukhyn, Dmytro, Turdean, Maria, Turna, Hande, Ursol, Grygoriy, Vanasek, Jaroslav, Varela, Mirta, Vallejo, Marcela, Vera, Luis, Victorino, Ana-Paula, Vlasek, Tomas, Vynnychenko, Ihor, Wang, Buhai, Wang, Jie, Wang, Kai, Wu, Yilong, Yamada, Kazuhiko, Yang, Chih-Hsin, Yokoyama, Takuma, Yokoyama, Toshihide, Yoshioka, Hiroshige, Yumuk, Fulden, Zambrano, Angela, Zarba, Juan Jose, Zarubenkov, Oleg, Zemaitis, Marius, Zhang, Li, Zhang, Xin, Zhao, Jun, Zhou, Caicun, Zhou, Jianying, Zhou, Qing, Zippelius, Alfred, Mok, Tony S K, Wu, Yi-Long, Kowalski, Dariusz M, Turna, Hande Z, Laktionov, Konstantin K, Lubiniecki, Gregory M, Zhang, Jin, Kush, Debra, Lopes, Gilberto

Source: In The Lancet 4-10 May 2019 393(10183):1819-1830

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Authors: Reck, Martin, Mok, Tony SK, Nishio, Makoto, Jotte, Robert M, Cappuzzo, Federico, Orlandi, Francisco, Stroyakovskiy, Daniil, Nogami, Naoyuki, Rodríguez-Abreu, Delvys, Moro-Sibilot, Denis, Thomas, Christian A, Barlesi, Fabrice, Finley, Gene, Lee, Anthony, Coleman, Shelley, Deng, Yu, Kowanetz, Marcin, Shankar, Geetha, Lin, Wei, Socinski, Mark A, Mok, Tony S K

Source: In The Lancet Respiratory Medicine May 2019 7(5):387-401

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Authors: Mok, Tony S K, Wu, Yi-Long, Kudaba, Iveta, Kowalski, Dariusz M, Cho, Byoung Chul, Turna, Hande Z, Castro, Gilberto, Srimuninnimit, Vichien, Laktionov, Konstantin K, Bondarenko, Igor, Kubota, Kaoru, Lubiniecki, Gregory M, Zhang, Jin, Kush, Debra, Lopes, Gilberto

Source: Lancet. 393(10183):1819-1830

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100142967214.0x000001&indx=1&recIds=ETOCvdc_100142967214.0x000001

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer

Authors: Lau, Sally C. M., Batra, Ullas, Mok, Tony S. K., Loong, Herbert H.

Source: Drugs. 79(8):823-831

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100130224243.0x000001&indx=1&recIds=ETOCvdc_100130224243.0x000001

De-novo and acquired resistance to immune checkpoint targeting

Authors: Syn, Nicholas L, Teng, Michele W L, Mok, Tony S K, Soo, Ross A

Source: In The Lancet Oncology December 2017 18(12):e731-e741

KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation.

Authors: Mok, Tony S. K., Yao, Wenxiu, Duruisseaux, Michaël, Doucet, Ludovic, Azkárate Martínez, Aitor, Gregorc, Vanesa, Juan-Vidal, Oscar, Lu, Shun, De Bondt, Charlotte, de Marinis, Filippo, Linardou, Helena, Kim, Young-Chul, Jotte, Robert M., Felip, Enriqueta, Lo Russo, Giuseppe, Reck, Martin, Michenzie, Mary F., Yang, Wenjing, Meade, Julie N., Barlesi, Fabrice

Source: Journal of Clinical Oncology; 2024 Supplement 17, Vol. 42, pLBA8509-LBA8509, 83p

Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK + non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.

Authors: Solomon, Benjamin J., Liu, Geoffrey, Felip, Enriqueta, Mok, Tony S. K., Soo, Ross Andrew, Mazieres, Julien, Shaw, Alice Tsang, de Marinis, Filippo, Goto, Yasushi, Wu, Yi-Long, Kim, Dong-Wan, Martini, Jean-Francois, Messina, Rossella, Paolini, Jolanda, Polli, Anna, Thomaidou, Despina, Toffalorio, Francesca, Bauer, Todd Michael

Source: Journal of Clinical Oncology; 2024 Supplement 17, Vol. 42, pLBA8503-LBA8503, 83p

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Authors: Soria, Jean-Charles, Wu, Yi-Long, Nakagawa, Kazuhiko, Kim, Sang-We, Yang, Jin-Ji, Ahn, Myung-Ju, Wang, Jie, Yang, James Chih-Hsin, Lu, You, Atagi, Shinji, Ponce, Santiago, Lee, Dae Ho, Liu, Yunpeng, Yoh, Kiyotaka, Zhou, Jian-Ying, Shi, Xiaojin, Webster, Alan, Jiang, Haiyi, Mok, Tony S K

Source: In The Lancet Oncology August 2015 16(8):990-998

Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI

Authors: Mann, Helen, Andersohn, Frank, Bodnar, Carolyn, Mitsudomi, Tetsuya, Mok, Tony S. K., Yang, James Chih-Hsin, Hoyle, Christopher

Source: Clinical drug investigation. 38(4):319-331

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100130229190.0x000001&indx=1&recIds=ETOCvdc_100130229190.0x000001

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

Authors: Mok, Tony S. K., Kim, Sang-We, Wu, Yi-Long

Source: Journal of clinical oncology. 35(36):4027-4034

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN614055441&indx=1&recIds=ETOCRN614055441

Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

Authors: Jiang, Peiyong, Chan, Carol W. M., Chan, K. C. Allen, Cheng, Suk Hang, Wong, John, Wong, Vincent Wai-Sun, Wong, Grace L. H., Chan, Stephen L., Mok, Tony S. K., Chan, Henry L. Y., Lai, Paul B. S., Chiu, Rossa W. K., Lo, Y. M. Dennis

Source: Proceedings of the National Academy of Sciences of the United States of America, 2015 Mar . 112(11), E1317-E1325.

Access URL: https://www.jstor.org/stable/26462104

Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography

Authors: Tan, Daniel S. W., Mok, Tony S. K., Rebbeck, Timothy R.

Source: Journal of clinical oncology. 34(1):91-101

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN604229583&indx=1&recIds=ETOCRN604229583

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

Authors: Ang, Yvonne L. E., Zhao, Xiaotian, Reungwetwattana, Thanyanan, Cho, Byoung-Chul, Liao, Bin-Chi, Yeung, Rebecca, Loong, Herbert H., Kim, Dong-Wan, Yang, James Chih-Hsin, Lim, Sun Min, Ahn, Myung-Ju, Lee, Se-Hoon, Suwatanapongched, Thitiporn, Kongchauy, Kanchaporn, Ou, Qiuxiang, Yu, Ruoying, Tai, Bee Choo, Goh, Boon Cher, Mok, Tony S. K., Soo, Ross A.

Source: Cancers; Oct2023, Vol. 15 Issue 20, p4999, 16p

Subject Terms: LUNG cancer, DRUG efficacy, RESEARCH, PATIENT aftercare, DNA, GENETIC mutation, SEQUENCE analysis, CONFIDENCE intervals, EPIDERMAL growth factor receptors, PARONYCHIA, PROTEIN-tyrosine kinase inhibitors, TREATMENT effectiveness, RESEARCH funding, PROGRESSION-free survival, DRUG side effects, DRUG resistance in cancer cells, LONGITUDINAL method, OVERALL survival, DISEASE risk factors, EVALUATION

Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations: A Review.

Authors: Passaro, Antonio, Mok, Tony S. K., Attili, Ilaria, Wu, Yi-Long, Tsuboi, Masahiro, de Marinis, Filippo, Peters, Solange

Source: JAMA Oncology; Aug2023, Vol. 9 Issue 8, p1124-1131, 8p

Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case—control study

Authors: Leung, Winnie Wing-man, Ho, Suzanne C, Chan, Henry L Y, Wong, Vincent, Yeo, Winnie, Mok, Tony S K

Source: Journal of Epidemiology and Community Health (1979-), 2011 Jun 01. 65(6), 556-558.

Access URL: https://www.jstor.org/stable/23050920

Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis

Authors: Li, Ming-Yue, Liu, Li-Zhong, Li, Wende, Ng, Calvin S. H., Liu, Yi, Kong, Angel W. Y., Zhao, Zhili, Wang, Shanshan, Qi, Haolong, Jia, Hao, Yang, Shucai, Du, Jing, Long, Xiang, Ho, Rocky L. K., Chak, Ernest C. W., Wan, Innes Y. P., Mok, Tony S. K., Underwood, Malcolm J., Gali, Nirmal Kumar, Ning, Zhi, Chen, George G.

Source: Journal of experimental & clinical cancer research. 38(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100129329582.0x000001&indx=1&recIds=ETOCvdc_100129329582.0x000001

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.

Authors: Socinski, Mark A., Jotte, Robert M., Cappuzzo, Federico, Nishio, Makoto, Mok, Tony S. K., Reck, Martin, Finley, Gene G., Kaul, Monika D., Yu, Wei, Paranthaman, Nindhana, Bāra, Ilze, West, Howard J.

Source: JAMA Oncology; Apr2023, Vol. 9 Issue 4, p527-535, 9p